Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.45 |
| ▸ | CDK1 | P06493 | 8/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | KAT7 | O95251 | 1/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206149 | 0.88 | CDK2 (0.49) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4495223 | 0.86 | CDK2 (0.54) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4503801 | 0.77 | CDK2 (0.49) | CDK2CDK1CDK4CCND1 | |
| SCHEMBL4199373 | 0.74 | CDK2 (0.52) | CDK2CDK1KCNH2 | |
| SCHEMBL4206968 | 0.74 | CDK2 (0.51) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4195833 | 0.74 | CDK2 (0.61) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4515739 | 0.74 | CDK2 (0.61) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4193060 | 0.73 | CDK2 (0.53) | CDK2CDK1KCNH2CDK4 | |
| SCHEMBL4507217 | 0.73 | CDK2 (0.49) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL4198006 | 0.72 | CDK2 (0.49) | CDK2CDK1KCNH2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | CDK2 3/4885CDK1 22/4885KCNH2 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.